EICHOR
● Completed
A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide
Condition: Metastatic Hormone-sensitive Prostate Cancer · Sponsor: Janssen-Cilag Ltd.
About this study
The purpose of this study is to assess the real-world outcomes differences between apalutamide or enzalutamide plus androgen deprivation therapy (ADT) for the treatment of participants with metastatic hormone-sensitive prostate cancer (mHSPC).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (53)
| Akh Wien | Vienna, Austria | — |
| Klinikum Wels Grieskirchen | Wels, Austria | — |
| Institut Sainte Catherine | Avignon, France | — |
| Institut Bergonie | Bordeaux, France | — |
| Polyclinique Bordeaux Nord Acquitaine | Bordeaux, France | — |
| Clinique Pasteur- Lanroze | Brest, France | — |
| Hopital Michallon CHU Grenoble Alpes | La Tronche, France | — |
| Hôpital Edouard Herriot | Lyon, France | — |
| Centre d'oncologie de Gentilly | Nancy, France | — |
| CHU Nimes | Nîmes, France | — |
| Hopital Europeen Georges-Pompidou | Paris, France | — |
| Hopital Tenon | Paris, France | — |
+ 41 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05901649